Tags

Type your tag names separated by a space and hit enter

Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet.
Horm Metab Res 2006; 38(6):417-22HM

Abstract

Skeletal demineralization and mineral metabolism derangement are well-recognized features of untreated celiac disease (CD). Although treatment with a gluten-free diet appears to prevent bone loss while correcting skeletal demineralization in childhood, there is evidence that bone mineral density does not return to normal in celiacs diagnosed in adulthood. Osteoprotegerin (OPG), a member of the tumor necrosis factor receptor family, and ligand of receptor activator of NFkB (RANKL) are involved in the process of bone turnover and have been implicated in the pathogenesis of osteoporosis and other metabolic bone diseases. We measured OPG, RANKL, bone mineral density (BMD), and biochemical markers of bone turnover in 32 adult female premenopausal celiac patients on a gluten-free diet, and thirty age-matched healthy women. We correlated the OPG/RANKL ratio with the severity of bone loss. Celiac patients had a mean BMD lower than controls in lumbar spine and in the femoral neck. Serum levels of bone alkaline phosphatase (BAP, marker of bone formation), and urinary excretion of telopeptides of type I collagen (a marker of bone resorption) were significantly higher than in controls. Serum OPG and RANKL levels were significantly higher in CD patients than in controls, while the OPG/RANKL ratio was significantly lower in CD patients than in controls and was positively correlated with BMD at the spine. The role of elevated OPG in CD patients is unclear, but it might represent a compensatory mechanism against other factors that promote bone damage. Further studies are required to assess a possible therapeutic potential of osteoprotegerin in optimally treated celiacs with persistent osteopenia.

Authors+Show Affiliations

Department of Internal Medicine, University of Catania, Catania, Italy. carmelo.fiore@tin.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16823725

Citation

Fiore, C E., et al. "Altered osteoprotegerin/RANKL Ratio and Low Bone Mineral Density in Celiac Patients On Long-term Treatment With Gluten-free Diet." Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, vol. 38, no. 6, 2006, pp. 417-22.
Fiore CE, Pennisi P, Ferro G, et al. Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet. Horm Metab Res. 2006;38(6):417-22.
Fiore, C. E., Pennisi, P., Ferro, G., Ximenes, B., Privitelli, L., Mangiafico, R. A., ... Lombardo, T. (2006). Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, 38(6), pp. 417-22.
Fiore CE, et al. Altered osteoprotegerin/RANKL Ratio and Low Bone Mineral Density in Celiac Patients On Long-term Treatment With Gluten-free Diet. Horm Metab Res. 2006;38(6):417-22. PubMed PMID: 16823725.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet. AU - Fiore,C E, AU - Pennisi,P, AU - Ferro,G, AU - Ximenes,B, AU - Privitelli,L, AU - Mangiafico,R A, AU - Santoro,F, AU - Parisi,N, AU - Lombardo,T, PY - 2006/7/11/pubmed PY - 2006/9/13/medline PY - 2006/7/11/entrez SP - 417 EP - 22 JF - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme JO - Horm. Metab. Res. VL - 38 IS - 6 N2 - Skeletal demineralization and mineral metabolism derangement are well-recognized features of untreated celiac disease (CD). Although treatment with a gluten-free diet appears to prevent bone loss while correcting skeletal demineralization in childhood, there is evidence that bone mineral density does not return to normal in celiacs diagnosed in adulthood. Osteoprotegerin (OPG), a member of the tumor necrosis factor receptor family, and ligand of receptor activator of NFkB (RANKL) are involved in the process of bone turnover and have been implicated in the pathogenesis of osteoporosis and other metabolic bone diseases. We measured OPG, RANKL, bone mineral density (BMD), and biochemical markers of bone turnover in 32 adult female premenopausal celiac patients on a gluten-free diet, and thirty age-matched healthy women. We correlated the OPG/RANKL ratio with the severity of bone loss. Celiac patients had a mean BMD lower than controls in lumbar spine and in the femoral neck. Serum levels of bone alkaline phosphatase (BAP, marker of bone formation), and urinary excretion of telopeptides of type I collagen (a marker of bone resorption) were significantly higher than in controls. Serum OPG and RANKL levels were significantly higher in CD patients than in controls, while the OPG/RANKL ratio was significantly lower in CD patients than in controls and was positively correlated with BMD at the spine. The role of elevated OPG in CD patients is unclear, but it might represent a compensatory mechanism against other factors that promote bone damage. Further studies are required to assess a possible therapeutic potential of osteoprotegerin in optimally treated celiacs with persistent osteopenia. SN - 0018-5043 UR - https://www.unboundmedicine.com/medline/citation/16823725/Altered_osteoprotegerin/RANKL_ratio_and_low_bone_mineral_density_in_celiac_patients_on_long_term_treatment_with_gluten_free_diet_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2006-944548 DB - PRIME DP - Unbound Medicine ER -